1.Progress of neoadjuvant immunotherapy in the treatment of locally advanced resectable esophageal carcinoma
Junjun HUANG ; Jiuhe SUN ; Shifa ZHANG ; Hongfeng LIU ; Ru SONG ; Qian WANG ; Liji CHEN ; Haibo CAI
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2024;31(07):1058-1065
Surgery is the preferred treatment for resectable esophageal cancer, but in locally advanced esophageal cancer, the effect of surgery alone is not ideal, so surgery-based comprehensive treatment is the best option. Neoadjuvant therapy has become a standard treatment in the treatment of locally advanced resectable esophageal cancer. Neoadjuvant therapy includes neoadjuvant chemotherapy, radiochemotherapy, immunotherapy, targeted therapy, etc. With the significant efficacy and acceptable toxicity of immunotherapy in the first-line and second-line treatment of advanced esophageal cancer, neoadjuvant immunotherapy has become a research hotspot of locally advanced resectable esophageal cancer. This article reviews the latest research progress and some limitations of neoadjuvant immunotherapy in locally advanced resectable esophageal cancer.
Result Analysis
Print
Save
E-mail